CD163 and soft tissue sarcoma: The discrepancy found with soft tissue sarcomas [24], in which CD163+ macrophages dominate over CD68+ macrophages, could be explained by the fact that CD68 is not only a macrophage-marker, but also, in the context of bone tissue, a marker of osteoclastic cells.